Mar 26 |
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
|
Mar 22 |
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions
|
Mar 7 |
Immunome to Participate in the Leerink Partners Global Biopharma Conference
|
Mar 1 |
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
|
Feb 20 |
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
|
Feb 20 |
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
|
Feb 16 |
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
Feb 14 |
Immunome down 1%, prices $200M equity
|
Feb 14 |
Immunome Announces Pricing of Public Offering of Common Stock
|
Feb 13 |
Immunome files for automatic mixed securities shelf
|